Bipolar disorder is characterized by intermittent episodes of mania and/or depression.1 Even with maintenance treatment, recurrences of manic or (more frequently) depressive episodes are common. Some of the drugs and dosages recommended here have not been approved by the FDA for use in bipolar disorder.
TREATMENT OF MANIA — Second-generation antipsychotics, lithium, and valproate are effective for treatment of acute manic episodes.2 Both lithium and valproate may take days to weeks to have a full therapeutic effect; treatment of an acute manic episode with these agents generally requires addition of an antipsychotic drug.
TREATMENT OF DEPRESSION — The second-generation antipsychotics quetiapine and lurasidone and the combination of olanzapine and fluoxetine have been shown to be effective in treating bipolar depression.3-6 Antidepressant...
- Cannabis and Cannabinoids
- Jentadueto XR for Type 2 Diabetes
- Emtricitabine/Tenofovir Alafenamide (Descovy) for HIV
- Venetoclax (Venclexta) for Chronic Lymphocytic Leukemia
- Addendum: Depression and Suicidality with Isotretinoin
The FDA has approved Epclusa (Gilead), a fixed-dose combination of sofosbuvir (Sovaldi) and velpatasvir, a new direct-acting antiviral agent, for oral treatment of chronic hepatitis C virus (HCV) infection. Epclusa is the first oral combination to be approved for treatment of all six major HCV genotypes.
HCV GENOTYPES — The prevalence of HCV genotypes in the US is about 75% for genotype 1, 20-25% for genotypes 2 and 3, and <2% for genotypes 4, 5, and 6 combined. Genotype testing is recommended to determine the optimal treatment ...